A cost-effectiveness analysis of the use of oral ibrexafungerp versus fluconazole for acute vulvovaginal candidiasis in the UK NHS primary care service
British Journal of General Practice · 2024
DOI: 10.3399/bjgp24x738189 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift British Journal of General Practice, 2024. Verfasst von Viraj Shah und 5 weiteren Autor:innen. Beteiligte Einrichtung: Imperial College London. Hauptthemen laut MEDLINE: Fluconazole, Cost-Benefit Analysis, Candidiasis, Vulvovaginal, Antifungal Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Background
Vulvovaginal Candidiasis (VVC) is a fungal infection causing inflammation of the vagina and/or the vulva. Symptoms include itching, irritation, and discharge. VVC presents commonly across primary care and, despite its mild symptoms, carries psychological burden and has a significant impact on women’s quality of life. UK guidelines support treatment via oral or topical azole antifungal agents. Recent evidence attests to the superiority of novel non-azole antifungals. Thus, rigorous financial assessment of both antifungals is necessary for optimal VVC treatment allocation in UK primary care.
Aim
To evaluate the cost-effectiveness of ibrexafungerp against the gold standard fluconazole as first-line treatment of VVC within the NHS.
Method
A systematic review on the efficacy of ibrexafungerp and fluconazole in acute VVC was conducted. Cost-effectiveness analysis was initiated using health outcome data from the DOVE trial, a Phase 2 RCT. Costs in pound sterling were ascertained in monetary units, and effectiveness determined as reduced need for follow-up medication.
Results
An incremental cost-effectiveness ratio of £2185.74 was determined. This suggests oral ibrexafungerp being largely more costly yet slightly more effective than fluconazole, and thus has unfavourable net benefit. Two sensitivity analyses were conducted considering follow-up medication combination and market price, which provided confidence in the calculated cost-effectiveness ratio.
Conclusion
This analysis highlights fluconazole’s cost-effectiveness in current UK guidelines and favourability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Imperial College London.
Zitieren
APA
Shah, V., Cyril, A., Koleoso, P., Ragutharan, A., Faiz, M., & Pushpakanthan, P. (2024). A cost-effectiveness analysis of the use of oral ibrexafungerp versus fluconazole for acute vulvovaginal candidiasis in the UK NHS primary care service. British Journal of General Practice. https://doi.org/10.3399/bjgp24x738189
Vancouver
Shah V, Cyril A, Koleoso P, Ragutharan A, Faiz M, Pushpakanthan P. A cost-effectiveness analysis of the use of oral ibrexafungerp versus fluconazole for acute vulvovaginal candidiasis in the UK NHS primary care service. British Journal of General Practice. 2024. doi:10.3399/bjgp24x738189
BibTeX
@article{Shah2024,
author = {Shah, Viraj and Cyril, Anjali and Koleoso, Peter and Ragutharan, Arunesh and Faiz, Mohammed and Pushpakanthan, Pathusha},
title = {A cost-effectiveness analysis of the use of oral ibrexafungerp versus fluconazole for acute vulvovaginal candidiasis in the UK NHS primary care service},
journal = {British Journal of General Practice},
year = {2024},
doi = {10.3399/bjgp24x738189}
}
EUVIMED